Michael Sheppard

1 - 10 out of 101Page size: 10

Publications

  1. Published

    Radioiodine treatment of hyperthyroidism - prognostic factors for outcome

    Amit Allahabadia, Michael Sheppard, Stephen Gough & Jayne Franklyn, 1 Aug 2001, In: Journal of Clinical Endocrinology and Metabolism. 86, 8, p. 3611-3617 7 p.

    Research output: Contribution to journal › Article

  2. Published

    Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles

    Michael Sheppard, 1 Jul 2005, In: Journal of Clinical Pharmacology. 45(7), p. 836-844 9 p.

    Research output: Contribution to journal › Article

  3. Published

    Does acromegaly enhance mortality?

    John Ayuk & Michael Sheppard, 1 Mar 2008, In: Reviews in endocrine & metabolic disorders. 9, 1, p. 33-9 7 p.

    Research output: Contribution to journal › Article

  4. Published

    Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly

    John Ayuk, Michael Sheppard, Paul Stewart & Andrew Bates, 1 Jan 2004, In: Journal of Clinical Endocrinology and Metabolism. 89, 4, p. 1613-1617 5 p.

    Research output: Contribution to journal › Article

  5. Published

    Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy

    John Ayuk, Suzanne Stewart, Paul Stewart & Michael Sheppard, 1 Jan 2004, In: Clinical Endocrinology. 60(3), p. 375-381 7 p.

    Research output: Contribution to journal › Article

  6. Published

    Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly

    John Ayuk, Paul Stewart & Michael Sheppard, 1 Sep 2002, In: Journal of Clinical Endocrinology and Metabolism. 87, 9, p. 4142-4146 5 p.

    Research output: Contribution to journal › Article

  7. Published

    Expression of 11beta hydroxysteroid dehydrogenase isozyme mRNAs in normal pituitary and pituitary adenomas

    John Ayuk, Kristien Boelaert, Michael Sheppard, Martin Hewison, Paul Stewart & Neil Gittoes, 1 Jan 2001, p. OC17.

    Research output: Contribution to conference (unpublished) › Paper

  8. Published

    The role of growth hormone-receptor antagonism in relation to acromegaly

    John Ayuk & Michael Sheppard, 1 Nov 2004, In: Expert Opinion on Pharmacotherapy. 5(11), p. 2279-2285 7 p.

    Research output: Contribution to journal › Review article

  9. Published

    Evidence for the Use of IGF-I as a Predictor of Mortality in Acromegaly Is Lacking

    John Ayuk, Michael Sheppard, Andrew Bates & Paul Stewart, 1 Nov 2004, In: Journal of Clinical Endocrinology and Metabolism. 89, 11, p. 5867-5868 2 p.

    Research output: Contribution to journal › Article

  10. Published

    Growth hormone and its disorders

    John Ayuk & Michael Sheppard, 1 Jan 2006, In: Postgraduate Medical Journal. 82, 963, p. 24-30 7 p.

    Research output: Contribution to journal › Review article

Previous 1 2 3 4 5 6 7 8 ...11 Next